- Design
- Two-centre, triple-blind randomised controlled trial
- Population
- 260 women with singleton term pregnancies needing induction, Nigeria
- Primary outcome
- Vaginal birth within 24 hours
- Effect
- 96.2% oral titrated vs 83.1% vaginal; fewer abnormal contraction and FHR patterns with oral
A two-centre, triple-blind randomised trial in Delta State, Nigeria, allocated 260 women with singleton term pregnancies to hourly titrated oral misoprostol solution or 25 mcg vaginal misoprostol every four hours. The primary outcome was vaginal birth within 24 hours.
Vaginal birth within 24 hours was 96.2% with the oral titrated regimen and 83.1% with vaginal tablets. The oral group also had fewer abnormal uterine contraction patterns, fewer abnormal fetal heart rate patterns and a lower caesarean rate. There was no uterine rupture in either arm.
The direction matches the larger trials behind current WHO and NICE advice favouring low-dose oral misoprostol. But the paper's reporting is muddled: the primary-outcome P value is printed in a form that does not establish significance, and the authors' own conclusion calls efficacy comparable. Read it as supporting existing practice rather than as new proof.
- Low-dose oral misoprostol is a reasonable first choice for term induction where your unit protocol allows it
- Monitor for tachysystole and fetal heart rate change with either route
- Avoid misoprostol in women with a previous caesarean scar
- Titrated oral solution needs a reliable way to prepare and measure small doses; check your pharmacy can supply it
Why it matters
Adds an African multicentre trial to the case for oral over vaginal misoprostol, where most induction evidence comes from high-income settings.
Don't overread it
Inconsistent statistical reporting means the efficacy difference should not be taken as established.
The statistics, in plain English
A 13-point difference in vaginal birth within 24 hours sounds large, but the abstract reports the P value inconsistently and the authors conclude efficacy was comparable. With 260 women, the trial is too small to measure rare harms such as uterine rupture; zero cases in each arm says little about that risk.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for obstetrics & gynaecology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free